Indaptus Therapeutics, Inc. Common Stock
INDPStock
$2.53−76.87%52W
Market Cap$286.50M
P/E—
Div yield—
Beta1.14
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-4.63%
Price vs S&P 500 (4W)-24.79%
VGM Score53.92
Market Capitalization$286.50M
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
INDPIndaptus Therapeutics, Inc. Common Stock | — | — | C | $2.53 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Indaptus Therapeutics is a pre-clinical biotechnology company developing a proprietary bacterial-based immunotherapy platform targeting cancer and viral infections. Its lead candidate, Decoy20, has demonstrated anti-tumor activity in preclinical models as both a single agent and in combination therapy across multiple cancer types, including colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.